Can you take Lansoprazole with Somatrogon?

Somatrogon has a major potential interaction with Acute Abdomen.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Somatrogon has a major potential interaction with Bladder Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Brain Tumor.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Breast Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a moderate potential interaction with Diabetes Mellitus.

Somatrogon may increase the risk of diabetes mellitus (DM) in patients with Turner syndrome. Monitor blood glucose levels periodically to assess for new onset diabetes in these patients. In patients with Turner syndrome and preexisting DM, monitor blood glucose more closely as adjustment of antidiabetic agents may be required when somatrogon is initiated.

Somatrogon has a moderate potential interaction with Diabetes Mellitus.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.

Somatrogon has a major potential interaction with Diabetic Retinopathy.

Somatropin, somatrogon , and lonapegsomatropin are contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy since treatment may worsen condition.

Lansoprazole has a major potential interaction with Diarrhea.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Lansoprazole has a moderate potential interaction with Liver Disease.

Lansoprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.

Somatrogon has a major potential interaction with Lung Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lansoprazole has a moderate potential interaction with Magnesium Imbalance.

Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.

Lansoprazole has a moderate potential interaction with Osteoporosis.

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

Somatrogon has a moderate potential interaction with Papilledema Associated with Increased Intracranial Pressure.

Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin, somatrogon , and lonapegsomatropin . Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

Somatrogon has a major potential interaction with Prostate Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lansoprazole has a major potential interaction with Pseudomembranous Colitis.

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Somatrogon has a major potential interaction with Pulmonary Impairment.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Somatrogon has a major potential interaction with Pulmonary Impairment.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Somatrogon has a moderate potential interaction with Scoliosis.

Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin and somatrogon increase growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin and somatrogon treatment.

Somatrogon has a major potential interaction with Sepsis.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Somatrogon has a major potential interaction with Skin Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Somatrogon has a major potential interaction with Sleep Apnea.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Somatrogon has a moderate potential interaction with Turner Syndrome.

Somatrogon may increase the risk of diabetes mellitus (DM) in patients with Turner syndrome. Monitor blood glucose levels periodically to assess for new onset diabetes in these patients. In patients with Turner syndrome and preexisting DM, monitor blood glucose more closely as adjustment of antidiabetic agents may be required when somatrogon is initiated.

Somatrogon has a moderate potential interaction with Turner Syndrome.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.

Somatrogon has a major potential interaction with Weight Loss.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Somatrogon has a moderate potential interaction with Weight Loss.

Treatment with growth hormone may decrease insulin sensitivity, inducing a state of insulin resistance and hyperglycemia, especially at higher doses. New onset type 2 diabetes mellitus (DM) or worsened glycemic control in patients with undiagnosed pre-diabetes or DM has been reported in patients receiving growth hormone. Monitor glucose levels in all patients during therapy with somatrogon, especially in those with who have glucose intolerance, or additional risk factors for diabetes (e.g., obesity, Turner syndrome, family history). Initiation of somatrogon in patients who have type 1 or 2 diabetes mellitus may require dose adjustment of anti-diabetic therapy.